Aclaris Therapeutics (ACRS)
(Delayed Data from NSDQ)
$1.15 USD
-0.06 (-4.96%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.15 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Cash flow Statements
Fiscal Year End for Aclaris Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -88.48 | -86.91 | -90.87 | -51.02 | -161.35 |
Depreciation/Amortization & Depletion | 0.86 | 0.80 | 0.92 | 1.32 | 24.91 |
Net Change from Assets/Liabilities | 9.39 | -1.20 | -1.34 | -2.36 | -2.70 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -0.10 | 19.74 | 39.15 | 13.42 | 42.70 |
Net Cash From Operating Activities | -78.33 | -67.57 | -52.13 | -38.63 | -96.45 |
Property & Equipment | -1.31 | -0.61 | -0.31 | -0.45 | -1.61 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 34.19 |
Investments | 47.53 | 13.23 | -167.32 | 6.84 | 73.11 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 46.22 | 12.63 | -167.63 | 6.39 | 105.68 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 26.81 | 72.90 | 239.66 | 18.72 | 0.21 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | -11.48 | -0.14 | -30.52 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.10 | -0.03 | -3.12 | -0.21 | 0.00 |
Net Cash from Financing Activities | 26.71 | 72.87 | 225.05 | 18.37 | -30.32 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -5.40 | 17.93 | 5.29 | -13.87 | -21.08 |
Cash at Beginning of Period | 45.28 | 27.35 | 22.06 | 35.94 | 57.02 |
Cash at End of Period | 39.88 | 45.28 | 27.35 | 22.06 | 35.94 |
Diluted Net EPS | -1.27 | -1.33 | -1.60 | -1.20 | -3.90 |
Fiscal Year End for Aclaris Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -27.93 | -16.94 | -88.48 | -86.99 | -57.73 |
Depreciation/Amortization & Depletion | 0.49 | 0.24 | 0.86 | 0.64 | 0.42 |
Net Change from Assets/Liabilities | -13.69 | -9.01 | 9.39 | -3.89 | -0.72 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 7.99 | 4.89 | -0.10 | 18.68 | 11.03 |
Net Cash From Operating Activities | -33.14 | -20.82 | -78.33 | -71.56 | -47.01 |
Property & Equipment | -0.12 | -0.14 | -1.31 | -0.87 | -0.78 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 16.28 | 16.97 | 47.53 | 39.54 | 6.92 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 16.16 | 16.83 | 46.22 | 38.67 | 6.14 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.00 | -0.06 | 26.81 | 26.76 | 26.74 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.07 | 0.00 | -0.10 | -0.10 | 0.00 |
Net Cash from Financing Activities | -0.07 | -0.06 | 26.71 | 26.66 | 26.74 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -17.04 | -4.04 | -5.40 | -6.24 | -14.13 |
Cash at Beginning of Period | 39.88 | 39.88 | 45.28 | 45.28 | 45.28 |
Cash at End of Period | 22.83 | 35.84 | 39.88 | 39.04 | 31.15 |
Diluted Net EPS | -0.15 | -0.24 | -0.02 | -0.41 | -0.42 |